The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Current & emerging treatments for patients with triple-class refractory multiple myeloma
Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, outlines current and emerging treatment strategies for patients with triple-class refractory multiple myeloma, which currently include belantamab mafodotin and selinexor. The recent introduction and development of CAR-T therapy and bispecific antibodies in this setting is changing the treatment landscape of patients with triple-class refractory disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
